Improving radical resection rates in patients with breast cancer by intraoperative imaging using bevacizumab-IRDye800CW the MARGIN-2 study Fluorescentie geleide borstsparende chirurgie als behandeling voor borstkanker: de MARGIN-2 studie
Latest Information Update: 18 Jul 2023
At a glance
- Drugs Bevacizumab (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- Acronyms the MARGIN-2 study
Most Recent Events
- 18 Jul 2023 New trial record